Likely candidates for this activation are IL-6 and G-CSF as neutralisation of IL6/G-CSF/MEK1/2 mitigated phosphorylation of ERK concomitant with reductions in cancer cell proliferation and invasion. Here, MAP2K1 is linked to cancer.